Agreements

Date: 2017-04-18

Type of information: Licensing agreement

Compound: EB66® cell line

Company: Bavarian Nordic (Denmark) Valneva (France - Austria)

Therapeutic area: Technology - Services - Infectious diseases

Type agreement: licensing

Action mechanism: EB66® cell line is a highly efficient platform for vaccine production. It is derived from duck embryonic stem cells and today represents a compelling alternative to the use of chicken eggs for large scale manufacturing of human and veterinary vaccines. To date, Valneva has more than 35 research and commercial agreements with the world’s largest pharmaceutical companies to utilize its EB66® technology. The first human vaccine using EB66® technology received marketing approval in 2014 and the first veterinary vaccine in 2012. To date, Valneva has more than 35 research and commercial agreements with the world’s largest pharmaceutical companies to utilize its EB66® technology.

Disease:

Details:

• • On April 18, 2017, Valneva announced that it has entered into a commercial agreement with Bavarian Nordic for the production of poxvirus-based vaccines using Valneva´s EB66® cell-line technology. The agreement grants Bavarian Nordic the rights to develop and commercialize multiple poxvirus-based vaccines on the EB66® cell-line. Bavarian Nordic’s vaccine candidates are currently produced on chicken embryonic fibroblast (CEF) and the company will explore the potential of switching to Valneva’s EB66® technology. Valneva will support Bavarian Nordic in establishing and optimizing the manufacturing process on EB66® for future large scale industrialization under a dedicated service agreement.

Financial terms: Financial terms of the agreements were not disclosed but do include upfront payments, milestones and future royalties on sales.

Latest news:

Is general: Yes